Cancer Profiling and Pathways: Technologies and Global Markets

October 19, 2010

Wellesley, Mass. – According to a new technical market research report, CANCER PROFILING AND PATHWAYS: TECHNOLOGIES AND GLOBAL MARKETS (BIO073A) from BCC Research (www.bccresearch.com), the global market value of cancer profiling and pathways technologies is an estimated $17.7 billion in 2010, but is expected to increase to $47 billion in 2015, for a 5-year compound annual growth rate (CAGR) of 21.6%.

The largest segment of the market, made up of proteomics, is projected to grow at a CAGR of 15.6% to reach $19.5 billion in 2015. Its value is estimated at nearly $9.5 billion in 2010.

The genomics segment is estimated at $6.6 billion in 2010, and is expected to increase at a 5-year CAGR of 9.7% to reach more than $10.5 billion in 2015.

The segment made up of epigenetic/methylation is projected to have a 5-year CAGR of 60.5%, rising from $1.6 billion in 2010 to $16.9 billion in 2015.

The smallest segment, made up of micro/RNA technology, is estimated to be worth $30.9 million in 2010 and is expected to increase by a CAGR of 26% to be worth $98.1 million in 2015.

Cancer biomarkers have gained significant importance in the drug-development process, and the market is an emerging segment. To gain an understanding of the market dynamics, market size, and competitive landscape, an analysis of the cancer biomarker market and cancer profiling technologies and new developments has to be detailed. This report’s exhaustive market segmentation captures relevant data regarding biomarker tools, services, and application markets, and thereby provides a complete picture of the cancer-profiling market.

The report covers epigenetic, methylation and miRNA products in development, products in clinical trials, and currently marketed and clinical-stage development products. It categorizes the biomarkers and profiling market, and provides market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook.

This report may prove crucial for the firms seeking investments in the cancer profiling sector. As market needs change with progress, the value of the information provided from microarrays, sequencing, and quantitative real time polymerase chain reaction (qRT-PCR) has become more relevant for markets outside of basic life-science research.

Cancer Profiling and Pathways: Technologies and Global Markets( BIO073A )
Publish Date: Sep 2010    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.